IRA Implications Will Factor Significantly In Deal Strategy In 2023
PwC Expects More Deals, But Affected By IRA
Executive Summary
A pair of new PwC reports project a more robust M&A environment in 2023, but questions about the impact of the Inflation Reduction Act are already affecting biopharma business development strategies.
You may also be interested in...
Going Into 2024, PWC Predicts Healthy Atmosphere For M&A
Quick accretion may be more important to acquirers than revenue growth potential, the firm’s annual outlook states. A variety of pressures will increase emphasis on strategic deal-making.
The Biggest M&A Announcements Of 2023 Show Deals Are Getting Bigger
M&A activity in 2023 began with March’s $43bn mega-deal for Seagen, but only one eight-figure takeout has occurred since. Still, the values are higher overall than seen in 2022 and might indicate a gradual return to larger deals.
Deal Watch: Sol-Gel To Tackle Gorlin Syndrome In Pact With BridgeBio’s PellePharm
Shoreline picks up technology platform rights and access from Editas, which recently reduced staff. Hyloris out-licenses commercial rights to Maxigesic in nine EU markets to Salus.